RXi Pharmaceuticals Initiates First Phase 2 Study with RXI-109
November 13, 2013 at 07:06 AM EST
RXi Pharmaceuticals Corporation (OTC: RXII ) today announced that the first patient has been enrolled in a Phase 2 study with the anti-scarring product RXI-109. In this study (RXI-109-1301), patients with a long hypertrophic scar in the lower abdominal area are eligible to receive scar revision surgery and subsequent
